Snowdon, Inc.

Snowdon Inc. is a pharmaceutical company that is focused on three major therapeutic areas with substantial market potential: acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicines. Snowdon’s pipeline extends from NCEs to repurposing off-patent drugs for new clinical indications. The company’s preclinical lead compound, SND-121, has shown exceptional safety and efficacy when administered orally in rodent models as a treatment for neuropathic pain. SND-121 appears to treat pain through a unique mechanism of action, distinct from traditional analgesics such as opioid narcotics, NSAIDs, or the antiepileptics gabapentin and pregabalin.

show less